Objectives: Develop and validate a Spanish society of contraception quality-of-life (SEC-QOL) questionnaire to assess the impact of contraceptive methods on the health-related quality of life (HRQOL) of women. Methods: SEC-QOL was developed following a standardized procedure including review of the literature, interviews with contraception users, and the administration of a pilot questionnaire to 187 women. SEC-QOL consists of 19 items and includes five dimensions. To validate the questionnaire, a multicenter, observational, prospective study was conducted in Spain. The following three study groups were defined: group A (n ϭ 129) comprised women using effective contraceptive methods; group B (n ϭ 251), comprised women about to start using an effective method; and group C (n ϭ 73) comprised women using no or poorly effective contraception. All women attended baseline and final visits (4 Ϯ 1 months). Participants completed the SEC-QOL, psychological well-being index, EuroQol five-dimensional questionnaire, and perceived health state questionnaires. Results: At baseline, women from group A had a better HRQOL in all SEC-QOL dimensions, except for breast symptoms. Heavier menstrual bleeding, more androgenic and breast symptoms, menstrual pain, and not using hormonal contraceptive methods were associated with lower HRQOL. SEC-QOL scores showed moderate correlations to psychological well-being index and slightly lower correlation to EuroQol five-dimensional questionnaire scores. At follow-up, HRQOL had improved in all groups; most markedly in group B, which obtained an average effect size of 0.59. The minimum important difference was established as a 3.4-point change in the global SEC-QOL score. SEC-QOL obtained a Cronbach's ␣ of 0.88 and an intraclass correlation coefficient of 0.82. Conclusions: SEC-QOL is a valid, reliable, and sensitive to change questionnaire for use in daily clinical practice and future research projects on contraception.
Introduction
The choice of a contraceptive method is mainly influenced by factors related to personal experience acquired from previously used methods, including the degree of satisfaction with the method and its influence on quality of life in general and sexuality in particular [1] [2] [3] . Other elements involved include the effectiveness and ease of use of the method, its potential effects on skin, and its influence on symptoms associated with the menstrual cycle [4, 5] (fluid retention, breast tension, abdominal swelling, excessive bleeding, and catamenial headache). Effects associated with the menstrual cycle have an influence on health-related quality of life (HRQOL), particularly in women who use hormonal methods [6 -8] that, because of their mechanism of action, significantly decrease most symptoms related to the menstrual cycle (premenstrual symptoms, dysmenorrhea, and amount and duration of bleeding) [9] .
To date, the few studies assessing the impact of use of the different contraceptive methods on HRQOL have used generic assessment tools [10] , such as instruments specific to psychiatry (quality of life enjoyment and satisfaction questionnaire) [8, 11, 12] or for directly assessing the impact of menstrual cycle (Moos menstrual distress questionnaire) [13] . None of these is a specific tool for assessing HRQOL in women of childbearing age using contraceptive methods. The objective of this project was to design and validate a questionnaire, the Spanish society of contraception quality-of-life (SEC-QOL) questionnaire, which would allow for specifically assessing the impact of contraceptive methods on the HRQOL of women and would help health-care professionals in contraceptive counseling.
Methods

Questionnaire development
The SEC-QOL questionnaire was developed following a standardized procedure. A comprehensive review of the scientific literature was first conducted to identify the questionnaire contents with an expert group. In addition, 14 interviews were also conducted with women of childbearing age (aged 18 -48 years) from different geographic areas of Spain who were using hormonal and nonhormonal contraceptive methods. The most relevant statements obtained from these interviews were used to prepare the questionnaire, which was subsequently administered to another group, this time consisting of 187 women. A preliminary analysis of the measurement properties of the questionnaire (internal consistency and feasibility) and a Rasch analysis to reduce the number of items were performed using the responses collected [14] . The pilot test allowed the number of questionnaire items to be reduced from 41 to 19 and gave a preliminary indication of the good measurement properties of SEC-QOL.
The final self-administered questionnaire consists of 19 items that allows for assessment of the following five dimensions: social (5 items), menstrual symptoms (4 items), breast symptoms (3 items), psychological (4 items), and sexual (3 items) (Appendix found in Supplemental Materials at 10.1016/j.jval.2011.08.1729). Each item allows for five Likert-like response choices (from "always" to "never" or from "totally agree" to "totally disagree" depending on the type of statement). Scores for the overall questionnaire and for each of its dimensions are obtained by adding the responses to the corresponding items, with subsequent standardization to a scale ranging from 0 (worst HRQOL) to 100 (best HRQOL). Standardization is obtained as follows: (actual scoreminimum score)/(maximum score -minimum score)*100.
Questionnaire validation
To validate the questionnaire, a multicenter, observational, prospective study was conducted in Spain from November 2008 to July 2009. Three study groups were defined based on the contraceptive method used. The first group ("group A") included women using effective contraceptive methods such as hormonal contraceptives, consistent use of barrier contraceptives, intrauterine devices, implants and injectables, male and female sterilization, and dual methods (e.g., combination of a hormonal method plus a barrier method). The main requirement was that this group of women continued using such methods for the following 4 months. The second group ("group B") included women who were not using any contraceptive method or were using a poorly effective contraceptive method (chemical contraceptives, inconsistent condom use, or natural methods) but who were to start using an effective method from the study recruitment visit and who would use the effective method for the following 4 months. Finally, the third group ("group C") comprised women who used no or poorly effective contraceptive methods and who, despite contraceptive counseling by the physician, decided that they would continue to use a poorly effective contraception or no contraception for the next 4 months. All women with diseases that could directly influence their daily life, women who had received a hysterectomy, women under study for infertility, women who had given birth within the previous 6 months, women who were or wanted to become pregnant, and women participating in a clinical trial at the time of study start were excluded from the study.
The women in Group B who did not continue with the contraceptive method of their group at the time of their final visit were reassigned to group C. In other words, the women in group B who did not use an efficient contraceptive method at the time of their second visit were analyzed as patients of group C. The women included in the group A (effective contraceptive methods) who changed or didn't continue using an effective contraceptive method, were eliminated from the analysis.
The study was approved by the ethics committee of Hospital Universitario de Guadalajara (Spain).
Sample size
The sample size required to assess the measurement properties of the SEC-QOL questionnaire was calculated for each study group. Women in group A were included to allow assessment of the testretest reliability of the questionnaire and were observed to obtain an intraclass correlation coefficient of 0.7 or higher, assuming a minimum ratio of 0.4. Assuming a significance level of 0.5, a statistical power of 0.80, and that 15% of patients would be lost to follow-up or were not evaluable, a sample size of 126 women was required.
Women in group B were included to allow assessment of sensitivity to change of the SEC-QOL. The sample size was calculated to detect changes in score of 0.2 standard deviations (small effect size [15] ) with a significance level of 0.05 and a statistical power of 0.80. Assuming 15% of patients would be lost to follow-up or not evaluable, the sample size calculated for this group was 231 women.
Finally, women in group C (or control group) were included to allow detection of differences between the other two groups of women using contraceptive methods (groups A and B) in SEC-QOL scores. For this, a ratio of one control for every three women from the other two groups was estimated. A sample size of 77 women was required to detect differences of 0.4 standard deviations or higher with a significance level of 0.05 and a statistical power of 0.80.
Study measurements
All women recruited into the study (Groups A, B, and C) attended two visits, a baseline visit and a final visit at 4 months (Ϯ1 month). At the baseline visit, the following were recorded: sociodemographic data (age, place of birth, educational level, and employment status); reason for consultation (regular check-up, contraceptive counseling, request for change in contraceptive method); current contraceptive method used and method to be used from that visit; menstrual interval (less than 21 days, 21 to 35 days, more than 35 days, and other); bleeding intensity (heavy, normal, scarce, or very scarce); presence or absence of pain related to menses (recorded using a 0 -10 visual analog scale [VAS]); presence of androgenic symptoms (acne, alopecia, oily skin, seborrheic dermatitis, hirsutism); presence of premenstrual breast symptoms (pain, increased sensitivity, enlargement, and breast discharge); obstetric history by recording the obstetric formula; and personal history of concomitant chronic diseases and life events (change of partner or relationship status, occupational changes, changes in family environment, housing and economic problems). At the final visit, the same variables were recorded, except for sociodemographic characteristics, reason for consultation, and reason for using contraceptives.
At both visits, study participants completed the specific SEC-QOL questionnaire, the psychological well-being index (PWI) [16] , and the EuroQol five-dimensional (EQ-5D) questionnaire [17] ; they were asked about their perceived health state using a Likert scale with five response options (from "very good" to "very poor"). All questionnaires were given to participants for completion before the interview with the physician.
Statistical method
A descriptive, comparative analysis of the sociodemographic and clinical characteristics of group A, B, and C study participants was performed. For group comparison, an analysis of variance (ANOVA) test with the Bonferroni correction was used for multiple comparisons of continuous variables, and a chi-square test was used for categorical variables. Changes in clinical variables and symptoms from baseline to the final visit were also compared in the different study groups using the same statistical tests.
The feasibility of SEC-QOL was assessed from the proportion of missing responses for each item and the proportion of women with valid responses to all questionnaire items. Mean time used to complete the questionnaire was also analyzed in groups A and B.
Validity, reliability, and sensitivity to change were assessed as measurement properties of SEC-QOL. Discriminant validity was first assessed by comparing the questionnaire scores of the different study groups, using an ANOVA test. In order to identify and describe which variables were related to HRQOL, a bivariate analysis was first performed, followed by a linear regression, including women from groups A and B and using as dependent variable the global SEC-QOL score at the second visit (because this was the visit for which more responses to the questionnaire from women using effective contraceptives were available). All sociodemographic and clinical variables, negative vital events, and the contraceptive method used were analyzed as independent variables.
To assess convergent validity, the relationship between the scores in the SEC-QOL and scores obtained in the PWI and VAS of the EQ-5D was analyzed using Pearson's correlation coefficient. Women from groups A and B were included in this analysis. Scores obtained in the questionnaire were analyzed based on the presence of problems in the items of the descriptive system of the EQ-5D questionnaire using a Student's t test.
To assess longitudinal validity, changes seen in scores in the SEC-QOL questionnaire from the baseline to the final visit were compared to the changes seen in clinical variables (menstrual interval, menstrual pain, bleeding intensity, breast symptoms, number of symptoms, and adverse event occurrence) during the same time period. For this, a Student's t test, an ANOVA test, and the Pearson's correlation coefficient were used depending on the type of variable analyzed. To assess sensitivity to change, the effect size (defined as the difference between the mean baseline and final scores, divided by the standard deviation obtained at baseline) obtained in SEC-QOL was calculated. The minimal important difference of the questionnaire (defined as the smallest difference in scores of a questionnaire perceived by the patient as beneficial) was estimated as the difference seen by women who stated that their health status had "slightly improved" at 4 months of study start.
Finally, the internal consistency and test-retest reliability of the specific questionnaire were assessed. Internal consistency was calculated using a Cronbach's ␣ statistic for all women participating in the study [18] (for both the overall questionnaire and dimension scores). Test-retest reliability was assessed in group A women using intraclass correlation coefficient.
SPSS for Windows version 15.0 (SPSS, University of Chicago, Chicago, IL) was used for statistical data analysis. A significance level of 0.05 was considered for all group comparisons.
Results
Sample description
A total of 453 women were included. Of these, 129 (28.4%) used effective methods and continued to use them after the baseline visit (group A), 251 (55.4%) did not use effective contraceptive methods and started to use them from the first study visit (group B), and 73 (16.1%) did not use effective contraceptive methods and did not use them throughout the study (group C). Table 1 provides the sociodemographic characteristics of study participants. Women in group C had a slightly higher mean age (33.6 years old) than women in the two other groups (29.3 years old in group A and 28.0 years old in group B) (P Ͻ 0.001). Statistically significant differences were also seen in educational level; 89.9% of women in group A stated that they had secondary or university education, compared with 76.5% and 79.2% in groups B and C, respectively (P ϭ 0.005). There were no differences in marital or occupational status.
In the final visit, two of the participants in group A did not accomplish the conditions of their group; i.e., they used inefficient contraceptive methods instead of using efficient contraceptive methods. For this reason those women were excluded from the analysis population. Final analysis of group A revealed that 127 women completed visit 1 and 108 women completed visit 2. Of the 251 women in group B, 197 completed the second visit. Of those 197, 10 did not change their contraception methods (they did not accomplish the inclusion criteria of group B). Those women accomplished the inclusion criteria of group C, and finally those women were included in this group. Therefore, for group B we considered 241 women in visit 1 and 187 women in visit 2. This means that, for group C, 83 women were considered for the basal visit (73 Ϯ10) and 8 of them did not complete the second visit (75 women on visit 2).
The main reason for consultation was a regular health check-up in 78.7% and 77.1% of women in groups A and C, respectively, whereas the most common reason (56.4%) in group B was contraceptive counseling. Among women who did not use any effective contraceptive method at baseline (women from groups B and C), the most common method was inconsistent condom use (78.8% and 62.7%, respectively), followed by coitus interruptus (18.7% and 24.1%). Among women using an effective contraceptive method at the baseline visit (group A), 42.5% stated that they used the contraceptive pill and 24.4% used condoms consistently ( Table  2) . With respect to the mean (SD) number of years women had been using the same contraceptive method, the longest period was found for group C women (6.4 [6.9], compared with 4.0 [3.9] and 3.8 [4.5] for women from groups A and B, respectively; P ϭ 0.001). Of women from group B who switched from a poorly effective to an effective contraceptive method, 38.6% were planning to change to the contraceptive pill. Besides contraception, regulation of the menstrual cycle was reported as another reason for starting contraceptive use by 23.6% of group A women and by 12.0% of group B women.
At the baseline visit, more than 84% of women in all groups had normal menstrual cycles (menstrual interval ranging from 21 and 35 days), with no significant differences between the different study groups. By contrast, statistically significant differences were found in bleeding intensity, which was greater among women from groups B and C than those from group A (P Ͻ 0.001). For this same variable, a statistically significant decrease was seen from the baseline to the final visit in group B women only (P Ͻ 0.001). With respect to menstrual pain, group A women had less pain than those from the two other groups (P Ͻ 0.001). However, a statistically significant decrease from the baseline to the final visit was only seen in group B women (P Ͻ 0.001). The most common androgenic symptoms were acne, oily skin, and greasy hair, but no statistically significant differences were seen between the groups. The number of androgenic symptoms decreased in group B women from the baseline to the final visit (P Ͻ 0.001). With regard to breast symptoms, the most common was an increased premenstrual breast tenderness, occurring in 44.4% of group A women and in 56.5% and 67.5% of women from groups B and C, respectively. Differences were seen between the groups in the number of breast symptoms. Women from group B were the only ones who reported a statistically significant decrease in the number of breast symptoms from the baseline to the final visit (P ϭ 0.002).
Validation of SEC-QOL Feasibility
A total of 96.4% women answered 100% of the items of SEC-QOL. The missing response rate was less than 2% in all questionnaire items. Mean administration time was 6.1 minutes. Figure 1 shows the baseline scores obtained in the SEC-QOL questionnaire by the different study groups. Statistically significant differences were seen between group A women (using effective contraceptive methods) and women from groups B and C (not using effective contraceptive methods until the time of visit) in all dimensions (P Ͻ 0.05), except for breast symptoms. Women from group A had a better HRQOL. Statistical significant differences in HRQOL between study groups were confirmed (P Ͻ 0.01) using a regression model adjusting by age and marital status.
Validation
When variables related to HRQOL were assessed by jointly analyzing women from groups A and B, a relationship was seen with menstrual bleeding and pain, but not with duration of menstrual interval. Women with a greater menstrual bleeding intensity also revealed reduced HRQOL according to the global SEC-QOL score (P Ͻ 0.01) as well as the scores for the menstrual symptom (P Ͻ 0.05) and psychological (pϽ0.01) dimensions. Women with more severe menstrual pain also indicated reduced HRQOL according to all SEC-QOL scores (global and by dimensions) (P Ͻ 0.02 for the sexual dimension and P Ͻ 0.01 for all other scores). IUD, intrauterine device.
The number of breast and androgenic symptoms experienced by study participants was found to have an impact on HRQOL. The number of breast symptoms experienced indicated a Pearson's correlation coefficient of 0.64 (P Ͻ 0.01) with the breast symptom dimension and a coefficient ranging from 0.13 to 0.37 (P Ͻ 0.05) with all other dimensions, except for the sexual dimension, which had a very low Pearson's correlation coefficient of 0.01 (P ϭ 0.94). The number of androgenic symptoms demonstrated a statistically significant but small (0.133) Pearson's correlation coefficient with the global SEC-QOL score.
A bivariate analysis revealed that women with a poorer HRQOL included those with greater menstrual bleeding intensity, more androgenic and breast symptoms, menstrual pain, and patients who did not use hormonal contraceptive methods. Subsequently, in the multivariate regression model, the variables found to be significant included breast symptoms (the greater their presence, the lower HRQOL), menstrual pain intensity (the greater the pain, the poorer HRQOL), and use of hormonal methods (better HRQOL among users of these methods) ( Table 3) .
SEC-QOL scores indicated moderate correlations to PWI scores. The highest correlation coefficients were found in the psychological dimension of SEC-QOL, followed by global score. The social and menstrual symptom dimensions of the SEC-QOL had a greater correlation to the vitality and general health dimensions of PWI than to all other questionnaire dimensions ( Table 4 ). The correlations observed in the EQ-5D VAS are Sexual D. slightly lower and reach the maximum coefficient with the global SEC-QOL score. When SEC-QOL scores were analyzed according to the level of problems in each of the EQ-5D dimensions, the greatest differences were seen in relation to pain/ discomfort, anxiety/depression, and daily activities ( Table 4 ).
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Fig. 1 -Mean baseline total and dimension scores by study group.
The relationship between the question about the perceived health state and SEC-QOL was statistically significant for all dimensions (P Ͻ 0.01) except for the sexual dimension. As presented in Figure 2 , HRQOL tended to improve in all study groups from the baseline to the final visit, but this improvement was more marked in women from group B. Only group A women had statistically significant improvements in the overall SEC-QOL score (P Ͻ 0.05) and in the psychological dimension (P Ͻ 0.01), whereas group B women had improvements in global score (P Ͻ 0.01) as well as the social (P Ͻ 0.01), psychological (P Ͻ 0.01), and sexual (P Ͻ 0.01) dimensions. Group B women had a HRQOL similar to group C women at baseline, but at the final visit their HRQOL was more similar to that of group A women (P Ͻ 0.01).
Sensitivity to change
The effect size (ES) obtained for all SEC-QOL scores were greater in group B women (0.14 to 0.59) compared with those in group A (0.06 to 0.24). In the overall score, group B women obtained an ES of 0.59 (large ES), compared with an ES of 0.22 for group A women (small ES) ( Table 5 ).
The minimum important difference in this study was established as a 3.4-point change in the global SEC-QOL score. Minimum important difference is defined as the mean change in questionnaire scores perceived by patients as an improvement in HRQOL.
Reliability
The SEC-QOL questionnaire demonstrated a good internal consistency, with an overall Cronbach's ␣ of 0.88 and a value higher than 0.70 in all dimensions, except for the sexual dimension (0.55). The overall intraclass correlation coefficient was 0.82, and was higher than 0.70 in all dimensions, thus indicating the good test-retest reliability of the questionnaire.
Discussion
Our results show the high feasibility, validity, sensitivity to change, and reliability of the SEC-QOL as a specific questionnaire to assess HRQOL in women of childbearing age who are using contraceptive methods. The SEC-QOL consists of only 19 items and may be administered in a short time. It is thus considered to be suitable for use in standard clinical practice.
Various studies on HRQOL and contraception have demonstrated that symptoms related to the menstrual cycle (fluid retention, breast tension, abdominal swelling, skin changes, heavy bleeding, or migraine associated to menstrual cycle), as well as symptoms such as depression, irritability, or mood changes are related to a poorer HRQOL [6, 19, 20] , which especially affects the physical dimension and mood in women. The impact of premenstrual symptoms on the daily life of women will depend on severity of such symptoms [21] . Because of the high prevalence of those symptoms in women of childbearing age (estimated to represent more than 70% in the United States [22] ), it is important to individually assess not only the number of symptoms, but the impact of regular occurrence of these symptoms on the life of women. The results achieved using the SEC-QOL questionnaire, developed using a methodology taking into account, in addition to published studies and expert opinions, the opinion of women of childbearing age using and not using contraceptive methods, reveal that previous or ongoing premenstrual symptoms have the greatest impact on the daily life of women. By contrast, aspects related to the efficacy of contraceptive methods do not appear to have a very significant impact on HRQOL because the questionnaire only includes one question directly related to this aspect.
With regard to premenstrual symptoms, this study found that premenstrual breast tension and intensity of menstrual bleeding are symptoms with a great impact on the life of women who experience them. Women already using some effective contraceptive method at the baseline visit (group A) had better scores in the menstrual and breast symptom dimensions than women who were to start an effective contraceptive method (group B). In addition, women who start a hormonal contraceptive method have also been shown to experience a significant improvement in symptoms related to the menstrual cycle during the study, an improvement also reflected in an increase in SEC-QOL scores. The relationship found between a greater bleeding intensity, a greater number of androgenic and breast symptoms, a higher severity of menstrual pain, and the use of nonhormonal contraceptive methods and a poorer quality of life agree with other studies relating use of hormonal contraceptives to a decrease in premenstrual symptoms [3, 23, 24] .
A study intended to assess the impact of oral contraceptive methods on quality of life (as assessed by the World Health Organization quality of life [WHOQOL]) in a Japanese population con- cluded that premenstrual symptoms had a great impact on the social, physical, and psychological dimensions [11] . These results also agree with those seen in the SEC-QOL, suggesting that group B women (with more premenstrual symptoms) have a greater impairment in the psychological and social dimensions than group A women (with less premenstrual symptoms). However, unlike generic questionnaires, the SEC-QOL includes specific dimensions related to premenstrual (breast) and menstrual symptoms that provide more specific information than the generic HRQOL questionnaires used to date, including the WHOQOL or short form 36 health survey. Results of this study indicate that the HRQOL of women of childbearing age who use contraception methods is highly related to severity of premenstrual symptoms and that the choice of hormonal contraceptive methods is highly focused on the minimization of such symptoms; not just obtaining the contraceptive effect. Although no change was made in the category of contraceptive method used by group A women during the study follow-up period, these women indicated a slight improvement in HRQOL. Such improvement may have been due, first of all, to the participation of women in this study, which resulted in closer medical monitoring of women (more visits and longer duration of visits) and an assessment by the physician of more relevant aspects perceptible by patients, such as HRQOL. Second, the fact that about 12% of group A women changed from using condom to hormonal contraceptive methods may have an impact on HRQOL.
The main limitation of this study is the follow-up period, which lasted 4 months, previous contraception studies defined a follow-up period between 3 and 6 months. Although 4 months may not appear long enough to assess changes in HRQOL score, particularly those related to premenstrual symptoms in group B women, this limitation is minimized by the finding of a high sensitivity to change (large ES) of the SEC-QOL in this group of women, which means that the questionnaire is able to detect even small changes in the health state of women.
In conclusion, this study permitted the evaluation of the measurement properties of the first HRQOL questionnaire specific for women of childbearing age who are using contraceptive methods. The results achieved suggest that the SEC-QOL is valid for use both in daily clinical practice and in future research projects to assess HRQOL of women on contraception. Finally, this study also demonstrated the significance and impact of premenstrual symptoms on HRQOL experienced by women of childbearing age.
